Thomas Malley - 29 Jun 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
Director
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
29 Jun 2023
Net transactions value
$0
Form type
4
Filing time
03 Jul 2023, 16:15:18 UTC
Previous filing
21 Jun 2023
Next filing
07 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Shares Options Exercise +5,000 5,000 29 Jun 2023 Direct F1
holding KNSA Class A Common Shares 71,967 29 Jun 2023 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Units Options Exercise $0 -5,000 -100% $0.000000* 0 29 Jun 2023 Class A Common Shares 5,000 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 Mr. Malley is the president of Mossrock Capital, LLC (Mossrock) and may be deemed to beneficially own the shares owned by Mossrock.
F3 The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs.